 |
| Quick Review |
|
| Cases/ Abstracts/ Factoids |
| Accepted Cases |
|
| Accepted Abstracts |
|
| Factoid |
| 2012 Press |
| Live Interviews |
|
| Daily Newspapers |
| 2012 Gallery |
|
|
|
 |
The most prominent faculty of the ANGIOPLASTY SUMMIT-TCTAP
2012 will share their experience and opinion in the interventional vascular
field.
|
Antonio
Colombo, MD 
EMO
Centro Cuore Columbus, San Raffaele Hospital, Italy
| Q > |
1. |
We want to learn how to do bifurcation stenting
successfully. Please tell us your strategy for bifurcation stenting. |
| |
|
(1) What are your criteria for planning 2-stents
implantation in bifurcation lesion? |
| |
|
(2) Do you think IVUS examination
is mandatory in bifurcation coronary stenting? |
| |
2. To reduce stent
thrombosis rate, what can we do during procedure? Please tell
us your treatment strategy in real practice. |
|
| |
|
|
William
F. Fearon, MD
Stanford
University Medicine Center, USA
| Q > |
1. FAME2 study was
halted the enrollment after only 2/3 of the planned patients
were included. Would you tell us how can we interpret this result?
What do you expect the result of 'ISCHEMIA' study? |
| |
2. Would you explain about functional
Syntax score? Please tell us the clinical meaning of this score.
|
| |
3. In real practice, It is not
easy to measure FFR for the ACS patients. Would you tell us
what is the role and benefit of FFR in the unstable angina or
NSTEMI patients? |
|
| |
|
|
William
A. Gray, MD
New
York-Presbyterian Hospital, Columbia University Medical Center,
USA
| Q > |
1. Would you explain
design and result of ACTIVE trial? What is the clinical impact
of this trial? |
| |
2. Would you explain the different
result between CREST trial and several mega-trials like SPACE,
ICSS? |
| |
3. What is the strong point of
CAS over CEA? To improve the CAS outcome, where should we focus
on? |
|
| |
|
|
Eberhard
Grube, MD
Elisabeth
Hospital Heart Center Rhein-Ruhr, France
| Q > |
1. What is the special
indication of valve-in-valve TAVR? |
| |
2. Please tell us the pro and
cons of CoreValve compared with Edward valve in TAVR? |
| |
3. Who will be the included as
potential candidates of TAVR in the future? |
|
| |
|
|
Ziyad
M. Hijazi, MD
Rush
University Medical Center, USA
| Q > |
1. What is the potential
limitation of current ASD devices? |
| |
2. Please tell us your tips to
improve success rate in very big ASDs. |
|
| |
|
|
David
Richard Holmes, MD
Mayo
Clinic, USA
| Q > |
1. Would you tell
us briefly about the most important message of 'PROTECT AF'
trial? |
| |
2. The results of recent clinical
studies for multivessel disease are discouraging to interventional
cardiologist. Do you think we have to change our mind in selecting
treatment option? |
| |
3. Please tell us how fatal the
procedure related complications are during Watchman device inplantation.
|
|
| |
|
|
Michael
R. Jaff, MD
Massachusetts
General Hospital, USA
| Q > |
1. We do not have
the answer for the optimal treatment strategy of renovascular
hypertension with renal artery stenosis. What is your treatment
strategy for renal artery stenosis? |
| |
2. Would you tell us the design
and current status of CORAL trial? What can we learn from CORAL
trial? |
| |
3. For preventing rupture, we
treat AAA with open surgical repair or endovascular therapy.
When can we treat the patients with medication and follow-up
instead of endovascular therapy? |
| |
4. Please tell us optimal treatment
strategy for the asymptomatic patients with carotid artery disease.
|
|
| |
|
|
David
E. Kandzari, MD
Piedmont
Heart Institute, USA
| Q > |
1. Please tell us
the rationale behind investigating renal denervation with RF
ablation for the treatment of refractory hypertension. |
| |
2. Would you briefly explain the
result of Simplicity-HTN1 and 2 trials? And also, could you
briefly introduce the ongoing clinical trial SYMPLICITY HTN-3?
|
| |
3. Currently, there are many efforts
to extend the indication of renal denervation to the patient
with sleep apnea, heart failure and chronic kidney disease.
Would you explain how renal denervation works on sleep apnea,
CHF and CKD? |
|
| |
|
|
Spencer
B. King III, MD
Saint
Joseph's Heart and Vascular Institute, USA
| Q > |
1. There have been
long-term debates regarding potential benefit of thrombus aspiration
during primary PCI in STEMI patients?
How about your opinion among routing aspiration vs. selective
aspiration vs. no aspiration? |
| |
2. Could you comment your opinion
regarding mostly optimal anticoagulation for ACS patients with
large thrombus burden? |
| |
3. As the Editor-in-chief of the
Major Cardiovascular Journal, which issues or topics should
be more answered from future trials in this field (i.e., STEMI
urgent PCI procedures)? |
|
| |
|
|
Martin
B. Leon, MD
NewYork-Presbyterian
Hospital, CUMC, USA
| Q > |
1. In this year ACC
meeting, long-term results of PARTNER Trial were presented.
Could you briefly summarize the potential clinical impact on
clinical practice? |
| |
2. Please tell us what are the
current limitations of TAVR devices? What is requirement for
the future TAVR system? |
| |
3. Would you explain what 'Dedicated
LM stent' is? What is the reason that 'Dedicated LM stent' is
needed? |
|
| |
|
|
Akiko
Maehara, MD
Cardiovascular
Research Foundation, USA
| Q > |
1. With VH-IVUS and
OCT images, What is your perspectives on 'temporal stability
of the plaques'? Are there any predictors for plaque stabilization?
|
| |
2. Are there any difference
in plaque distribution and composition between Left Main bifurcation
and non Left Main Bifurcations? What would be clinical implication
of the observations in terms of treatment strategy and PCI outcomes
for bifurcation lesions? |
| |
3. |
(1) Do you think if the criteria based on FFR>0.80
would be safe for deferral? If it is not enough, what do you
consider to decide to treat or not to treat? |
| |
|
(2) Would you address the role of
IVUS compared to FFR during LM PCI? |
| |
4. In a practical
point of view, what do you think of clinical utility of OCT
during the PCI? |
|
| |
|
|
Roxana
Mehran, MD
Mount
Sinai Hospital, USA
| Q > |
1. We have many available
anti-platelet agents up to now. However it is not easy to optimize
antiplatelet therapy according to the each patient characteristic.
Would you give us practical guideline for the personalized medical
treatment? |
| |
2. Bleeding is important factor
can influence on the mortality as much as ischemia. Would you
tell us the risk factors for Bleeding based on your study? Also
could you tell us the clinical impact of the bleeding risk score
model? |
| |
3. Currently we are conducting
mach kind of global clinical trials. Would you tell us what
is advantages and disadvantages of global clinical trial? To
improve the quality of global clinical trial, what should we
more focus on? |
|
| |
|
|
Gary
S. Mintz, MD
Cardiovascular
Research Foundation, USA
| Q > |
1. We have many sort
of imaging modalities to evaluate coronary lesions (IVUS, OCT,
NIRS and FFR.., What is your strategy to select the imaging
modalities to get optimal information? |
| |
2. Please explain how to improve
the appropriate usage and interpretation of the imaging modalities
in the cath-lab. |
| |
3. Would you address what are
the key messages from the PROSPECT trial? And, what would be
the perspectives of future imaging study? |
|
| |
|
|
Nico
Pijls, MD
Cathrina
Hospital, Netherlands
| Q > |
1. Please explain
the concept of 'functional complete revascularization'. What
is clinical impact of 'functional complete revascularization'?
|
| |
2. What are your perspectives
on the treatment ofmulti-vessel coronary artery disease? Would
you explain what the difference between SYNTAX and FAME trial
is? |
| |
3. FAME trial has changed practical
pattern to FFR-guided PCI and many studies with FFR are ongoing
now. What do you expect future direction of functional angioplasty
with FFR? |
|
| |
|
|
Horst
Sievert, MD
CardioVascular
Center Frankfurt, Germany
| Q > |
1. Can you suppose
how many hypertensive patients will be the potential candidates
of renal denervation? |
| |
2. New antithrombotic drugs are
recently approved for prevention of stroke in atrial fibrillation
patients. Do you think what will be the future role of LAA closure
device? |
| |
3. Renal denervation is currently
contraindicated for renal failure patients. Is there a possibility
to expand the indication of renal denervation to those patients?
|
|
| |
|
|
Gregg
W. Stone, MD
Columbia
University Medical Center, Cardiovascular Research Foundation, USA
| Q > |
1. The results of
MAIN-COMPARE, SYNTAX, and PRECOMBAT have already been reported.
What is the additional important question in the EXCEL trial? |
| |
2. Based on the results of ACUITY,
HORIZON and INFUSE-AMI trials, how do you recommend treating
high-risk ACS patients using bivalirudin and GP IIb/IIIa inhibitors? |
| |
3. Please provide your daily practice
in deciding the treatment option between CABG and PCI for multivessel
disease. Do you think the SYNTAX score should be a primary factor
for our decision-making in all patients? |
|
| |
|
|
Corrado
Tamburino, MD
Ferrarotto
Hospital University of Catania, Italy
| Q > |
1. Would you briefly
explain the good points and bad points of the current SYNTAX
score for LM revascularization? |
| |
2. What is the best or most predictive
risk score for outcomes from the NERS, CSS, GRC etc? |
| |
3. Recently you presented the
result of 'Italian Core valve registry'. What can we learn from
the result of the registry? |
| |
4. In routine practice, there
are several patients having combined significant coronary artery
disease and severe AS, but not eligibile open heart surgery?
In these patients, which procedure would be first? Would you
tell us when the appropriate time to do PCI is? |
|
| |
|
|
Renu
Virmani, MD
CV
Path Institute, Inc., USA
| Q > |
1. As pathologic point
of view, would you tell us what structural features predict
plaque vulnerability? |
| |
2. In clinical practice, it is
not easy to define how big necrotic core or how thin fibrous
cap is vulnerable plaque.
Based on your pathologic studies, would you give us your perspectives
on this matter? |
| |
3. CV path constantly has published
about pathologic findings in relation to atherothrombotic disease.
Would you explain the mechanism of plaque progression? Can you
tell us what will be the next target for new drug to stabilize
the plaque? |
|
| |
|
|
Stephan
Windecker, MD
Swiss
Cardiovascular Center, Switzerland
| Q > |
1. Recently, long-term
four-year results from the LEADERS trial was reported and published.
Would you brief introduce the key findings and explain the clinical
impact on our future clinical practice? |
| |
2. Would you briefly explain the
future scenario of upcoming DES? What would be a winner after
5 years later among polymer free DES, biodegradable polyer DES,
or bioabsorbable stent? |
| |
3. Could you introduce your preference
of specific DES according to clinical or lesion characteristics?
|
|
|
|
|
|
|
